尼尔塞维马布对婴儿呼吸道共囊病毒的重症监护室入院的有效性 - 24个州,2024年12月至2025年4月
MMWR. Morbidity and mortality weekly report
|December 5, 2025
概括
尼尔塞维马布有效地保护婴儿免受严重的呼吸道同胞病毒 (RSV) 疾病的影响. 这种长效抗体显著减少了婴儿在第一个RSV季节的重症监护室入院和急性呼吸衰竭.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 呼吸道同胞病毒 (RSV) 是美国婴儿住院和呼吸衰竭的主要原因.
- 尼尔塞维马布是一种长效单克隆抗体,推用于婴儿RSV预防.
- 关于nirsevimab在治疗严重RSV结局 (如ICU入院和严重呼吸道疾病) 的有效性数据有限.
研究的目的:
- 为了评估nirsevimab对RSV相关的婴儿重症监护室 (ICU) 入院的有效性.
- 在住院婴儿中评估nirsevimab对RSV相关急性呼吸衰竭的有效性.
主要方法:
- 从2024年12月到2025年4月进行了27家医院的病例控制研究.
- 病例患者有RSV相关的ICU入院;对照患者有负的RSV测试,但有类似的症状.
- 在症状出现前≥7天接受nirsevimab的情况进行了分析.
主要成果:
- 尼尔塞维马布在与RSV相关的ICU入院方面表现出80%的有效性.
- 尼尔塞维马布在与RSV相关的急性呼吸衰竭方面显示出83%的有效性.
- 当尼尔塞维玛布在症状出现前50-52天的中位数被给予时,观察到有效性.
结论:
- 尼尔塞维马布在预防婴儿严重RSV结局方面非常有效.
- 这些发现支持nirsevimab在保护婴儿免受严重RSV疾病方面的作用.
- 尼尔西维玛是婴儿RSV预防策略的宝贵工具.
更多相关视频
相关概念视频
Acute Respiratory Failure-II
988
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
988
Acute Respiratory Failure-I
797
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
797
Acute Respiratory Failure-IV
490
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
490
Acute Respiratory Failure-V
425
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
425
Acute Respiratory Failure-III
733
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
733
Pneumonia IV: Management
731
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
731


